All News

NeurologyLive Friday 5 — September 18, 2020

September 18, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.

Luc Truyen, MD, PhD: Long-Term Results of Ponesimod in Phase 2b Study

September 18, 2020

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.

The Metamorphosis of Migraine: Evidence and Epidemiology

September 18, 2020

The ongoing fight to add to the epidemiologic understanding of migraine is explored in part 2 of this special 3-part multimedia series on the evolution of migraine care.

Indu Subramanian, MD: Social Prescribing for Patients With Parkinson Disease

September 18, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers explained how social prescribing can play a key role in the prevention of social isolation.

Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

The Changing Treatment Landscape for Acute Migraine

September 18, 2020

David Dodick, MD, reviews changes to the treatment landscape for acute migraine.

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Stewart Factor, MD: Long-Term Data on Apomorphine Sublingual Film in Parkinson

September 17, 2020

The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.

Addressing Loneliness and Social Isolation in Patients With Parkinson Disease

September 17, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Two posters presented at MS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.